Back
Entrada Therapeutics Quote, Financials, Valuation and Earnings
The Mysterious VC Firm Behind Nvidia's Secret Weapon
Details Here!
Buy
64
TRDA
Entrada Therapeutics
Last Price:
19.01
Seasonality Move:
-34.31%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE TradeEntrada Therapeutics Price Quote
$19.01
+0.39 (+2.09%)
(Updated: November 6, 2024 at 10:25 AM ET)
Entrada Therapeutics Key Stats
Buy
64
Entrada Therapeutics (TRDA)
is a Buy
Day range:
$17.25 - $18.62
52-week range:
$10.75 - $18.62
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.69
P/B ratio:
1.61%
Volume:
153.7K
Avg. volume:
119.8K
1-year change:
11.83%
Market cap:
$692.7M
Revenue:
$129M
EPS:
$2.96
How Much Does Entrada Therapeutics Make?
-
How Much Are Entrada Therapeutics's Sales Annually?
TRDA Revenues are $129M -
How Much Profit Does Entrada Therapeutics's Make A Year?
TRDA net income is -$6.7M
Is Entrada Therapeutics Growing As A Company?
-
What Is Entrada Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 4.21% -
What Is Entrada Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Entrada Therapeutics Stock Price Performance
-
Did Entrada Therapeutics Stock Go Up Last Month?
Entrada Therapeutics share price went up by 9.08% last month -
Did TRDA's Share Price Rise Over The Last Year?
TRDA share price rose by 11.83% over the past 1 year
What Is Entrada Therapeutics 52-Week High & Low?
-
What Is Entrada Therapeutics’s 52-Week High Share Price?
Entrada Therapeutics has traded as high as $18.62 over the past 52 weeks -
What Is Entrada Therapeutics’s 52-Week Low Share Price?
Entrada Therapeutics has traded as low as $10.75 over the past 52 weeks
Entrada Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Entrada Therapeutics?
-
How Much Debt Does Entrada Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Entrada Therapeutics Have?
Cash and short term investments quarterly total is $469.7M -
What Is Entrada Therapeutics’s Book Value Per Share?
Book value per share is 11.57
Is Entrada Therapeutics Cash Flow Positive?
-
What Is TRDA Cash Flow From Operations?
Cash flow from operations (TTM) is -$14.2M -
What Is Entrada Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $102.6M -
What Is Entrada Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $17.1M
Entrada Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
TRDA return on invested capital is 37.43% -
What Is Entrada Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 20.55% -
What Is TRDA Return On Equity?
ROE is a measure of profitability and is 37.43%
Entrada Therapeutics Earnings Date & Stock Price
-
What Is Entrada Therapeutics's Stock Price Today?
A single share of TRDA can be purchased today for 18.62 -
What Is Entrada Therapeutics’s Stock Symbol?
Entrada Therapeutics trades on the nasdaq under the ticker symbol: TRDA -
When Is Entrada Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Entrada Therapeutics is scheduled on November 7, 2024 -
When Is TRDA's next ex-dividend date?
Entrada Therapeutics's next ex-dividend date is November 6, 2024 -
How To Buy Entrada Therapeutics Stock?
You can buy Entrada Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Entrada Therapeutics Competitors
-
Who Are Entrada Therapeutics's Competitors?
Below is a list of companies who compete with Entrada Therapeutics or are related in some way:
Entrada Therapeutics Dividend Yield
-
What Is TRDA Dividend Yield?
Entrada Therapeutics’s dividend yield currently is 0% -
What Is Entrada Therapeutics’s Payout Ratio?
Entrada Therapeutics’s payout ratio is 0% -
When Did Entrada Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 6, 2024 -
What Is Entrada Therapeutics’s Dividend Per Share?
Entrada Therapeutics pays a dividend of $0.00 per share
Entrada Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 44% |
| Revenue: | 421.16% | 64.8% |
Analyst Recommendations
| Buy Recommendations: | 4 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 23.90 |
| Upside from Last Price: | 28.37% |